[1] Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells:CARs take the front seat forhematologic malignancies[J]. Blood, 2014, 123(17):2625-2635.
[2] 陈杰, 王宇环, 罗成林, 等. 嵌合抗原受体T细胞介绍及抗肿瘤临床应用[J]. 中国细胞生物学学报, 2014, 36(2):228-235.
[3] 张少华,毕经旺. 嵌合抗原受体修饰T细胞在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志,2014,41(7):495-499.
[4] Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med,2014,371(16):1507-1517.
[5] 徐云云, 金润铭. 血液肿瘤治疗中嵌合抗原受体基因修饰T淋巴细胞作用[J]. 中国实用儿科杂志,2013,28(8):626-629.
[6] Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma[J].Blood,2011,118(23):6050-6056.
[7] Lamers CH, Sleijfer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells:clinical evaluation and management of on-target toxicity[J]. Mol Ther,2013,21(4):904-912.
[8] Rizvi NA, Mazières J, Planchard D, et al.Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2,single-arm trial[J]. Lancet Oncol,2015, 16(3):257-265.
[9] Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance[J]. Nature, 2014,515(7528):568-571.
[10] Rozali EN, Hato SV, Robinson BW, et al. Programmed death ligand 2 in cancer-induced immune suppression[J]. Clin Dev Immunol,2012,2012:656340.
[11] John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells[J]. Clin Cancer Res,2013,19(20):5636-5646.
[12] John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy[J]. Oncoimmunology,2013,2(10):e26286.
[13] Yan Y, Li S, Jia T, et al. Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity[J].Tumour Biol,2015,36(6):4535-4543.
[14] Nishio N, Diaconu I, Liu H, et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors[J].Cancer Res,2014,74(18):5195-5205.
[15] 鹿萍,郝莎, 袁卫平,等.嵌合抗原受体——癌症免疫治疗的新希望[J]. 中华医学杂志,2015,95(4):311-314.
[16] Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors[J]. Nat Med,2015,21(6):581-590.
[17] Song DG, Ye Q, Carpenito C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137(4-1BB)[J]. Cancer Res,2011,71(13):4617-4627.
[18] Zhao Z, Condomines M, van der Stegen SJ, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells[J]. Cancer Cell,2015,28(4):415-428.
[19] Prapa M, Caldrer S, Spano C, et al. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing[J]. Oncotarget,2015,6(28):24884-24894.
[20] Ahmed N, Brawley VS, Hegde M, et al. Human epidermal growth factor receptor 2(HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma[J]. J Clin Oncol,2015,33(15):1688-1696.
[21] Maus MV, June CH. CARTs on the road for myeloma[J]. Clin Cancer Res,2014,20(15):3899-3901.
[22] Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design[J]. Cancer Discov,2013,3(4):388-398.
[23] Kalaitsidou M, Kueberuwa G, Schutt A, et al. CAR T-cell therapy:toxicity and the relevance of preclinical models[J]. Immunotherapy,2015,7(5):487-497.
[24] 蔡慧, 赵莲君, 邹征云. 嵌合抗原受体基因修饰T淋巴细胞在肿瘤免疫治疗中的研究[J]. 现代肿瘤医学,2014, 22(11):2730-2734.
[25] Liu X, Jiang S, Fang C, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice[J]. Cancer Res,2015,75(17):3596-3607.
[26] Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells[J]. Nat Biotechnol,2013,31(1):71-75.
[27] Wilkie S, van Schalkwyk MC, Hobbs S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling[J]. J Clin Immunol,2012,32(5):1059-1070.
[28] Caruso HG, Hurton LV, Najjar A, et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity[J]. Cancer Res,2015,75(17):3505-3518.
[29] Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J]. Sci Transl Med,2014,6(224):224-225.
[30] Wu CY, Roybal KT, Puchner EM, et al. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor[J].Science,2015,350(6258):aab4077.